Arch Clinical Trials, LLC

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Schizophrenia3 trials
• Depression1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Boehringer Ingelheim1 trial
• Definium Therapeutics US, Inc.1 trial
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
• Novartis Pharmaceuticals1 trial

Running trials

• Recruiting

  A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  NCT07592689· Phase 3· Definium Therapeutics US, Inc.· Source

  Contact: Erica Ehrhardt

• Recruiting

  Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

  NCT07467993· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Syed Junaid (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Boehringer Ingelheim· Source